Background {#Sec1}
==========

The increasing contribution of cardiovascular magnetic resonance (CMR) in clinical management is due to its accurate measurements and versatility of the imaging readouts, providing a comprehensive assessment of cardiac function and structure. Insights provided by tissue characterization using late gadolinium enhancement (LGE) imaging, inform on the underlying etiology, relate to prognosis and guide treatment \[[@CR1]-[@CR5]\]. LGE relies on visual and semi-quantitative determination of relative myocardial differences commonly presenting with characteristic patterns of LGE distribution \[[@CR6]\]. As it requires regional relative differences between normal and abnormal tissue, it is limited in revealing diffuse myocardial disease, where abnormal and normal tissue are intertwined \[[@CR7]\]. Recent advances in image acquisition and quantitative postprocessing now allow fast tissue characterisation based on the absolute quantifiable differences in recovery rates of longitudinal magnetisation by T1 mapping \[[@CR8]\]. T1 mapping is emerging as a robust and highly reproducible application to provide meaningful measures reflecting biologically important myocardial properties \[[@CR9]\]. Currently proposed T1-based indices and potential novel measures include *native T1*, which reflects myocardial disease involving the myocyte and interstitium without the need for gadolinium based contrast agents (GBCA); and *extracellular volume fraction (ECV)*, a direct GBCA-based measurement of the size of the extracellular space, reflecting only interstitial disease. Emerging evidence shows that myocardial T1-values correlate with the content of underlying myocardial fibrosis, they are abnormal in a variety of heart conditions and also reflect pathological substrates such as oedema or infiltration \[[@CR9]\].

Despite a recognized potential for clinical application, there is an identified lack of standardization and transferability of T1 mapping methods beyond a single and commonly expert center. Setups of available T1 mapping methods are presently site and vendor specific, with variable accuracy and precision of T1 values between the systems and sequences \[[@CR10]\]. Considerable differences in image acquisition, post-processing approaches and proposed clinical applications further complicate the use of T1 values as standard application in clinical decision-making \[[@CR11],[@CR12]\]. Finally, because T1 mapping is presently used in a research (or work-in- progress, WIP) domain and not yet a clinical product for all vendors, the experience is concentrated to a few specialist centers. We established a multicenter consortium of CMR centers that adopted a uniform T1 mapping methodology, which is supported by a single vendor platform. We assessed the transferability of a T1 mapping method in terms of the standardized acquisition and postprocessing approach, and determined biological reference values of human myocardium in a multicenter setting.

Methods {#Sec2}
=======

Multicenter consortium {#Sec3}
----------------------

Standardized T1-mapping sequence and imaging protocol, developed and validated at King's College London (KCL) \[[@CR13]-[@CR16]\], were distributed to 4 CMR centers using 1.5 and 3 T Philips scanners (University of Leeds (UL), United Kingdom; German Heart Institute Berlin (DHZB), Germany and St Vincent University (StVU), Sydney, Australia). The participating centers were identified via the worldwide Philips Healthcare clinical science network and hold individual partnership research agreements, allowing for adequate clinical science support and provision of compatible sequences and scanner software packages. Imaging parameters were unified across participating sites. Concordance of local T1-values with KCL values was established in preliminary experiments using standardized phantoms (Eurospin II Test System®) at each location for each field strength, as well as healthy subjects scanned at each location. The respective local ethical review panels approved the study protocols and all subjects provided written informed consent.

Study population {#Sec4}
----------------

Healthy subjects with no significant medical history, no evidence of cardiovascular disease (normal ECG, normal cardiac dimensions and function by cine CMR, normal tissue characterization) or taking any regular medication, were included (n = 102). An independent group of normotensive subjects referred for clinical CMR with a low pretest probability of cardiomyopathy or cardiac disease, taking no medication, and with subsequently normal findings on routine CMR, were used as a comparative cohort (n = 113) \[[@CR17]\]. Characteristics were recorded for all subjects, including age, gender, body mass index, heart rate and blood pressure. Exclusion criteria were the generally accepted contraindications to CMR (implantable devices, cerebral aneurysm clips, cochlear implants, severe claustrophobia) or a history of renal disease with a current eGFR \< 60 mL/min/1.73 m2.

CMR protocol {#Sec5}
------------

CMR studies were performed with the patient supine using clinical 1.5 T or 3 T scanners (Achieva or Ingenia, Philips Healthcare, Best, The Netherlands) equipped with advanced cardiac package, radiofrequency magnetic field shimming (MultiTransmit) technology and a 32-channel coil. Subjects underwent a standardized imaging protocol for assessment of cardiac function and size, as described previously \[[@CR14]-[@CR16]\]. Contrast-enhanced study was performed in a total of 179 subjects (healthy volunteers, n = 66, 65%; low risk subjects, n = 113, 100%). Balanced steady state free precession, single breath-hold modified inversion recovery Look-Locker (MOLLI) was used for T1 mapping and performed in a single mid-ventricular short axis slice, prior to contrast administration and to scar imaging, respectively (TE/TR/flip-angle (FA): 1.64 ns/3.3 ns/50°, voxel size 1.8 × 1.8 × 8 mm, phase encoding steps n = 166, 11 images from three inversions (3 + 3 + 5) with three-heartbeat pauses prior to the second and third inversions and an adiabatic prepulse) \[[@CR13]-[@CR16]\]. Intravenous gadobutrol (Bayer Healthcare, Leverkusen, Germany) was administered in doses 0.1, 0.15 or 0.2 mmol/kg per body weight, as per the local clinical protocol.

Image analysis {#Sec6}
--------------

All routine CMR analysis was performed using commercially available software (ViewForum, Extended Workspace, Philips Healthcare, The Netherlands), as previously described \[[@CR14]-[@CR16]\].

Myocardial T1 relaxation was measured by placing a region of interest (ROI) conservatively within the septal myocardium, as previously described \[[@CR13]-[@CR16]\] (Figure [1](#Fig1){ref-type="fig"}). T1 values were also measured for the complete mid-ventricular SAX slice as well as for 6 equiangular segments (7--12) \[[@CR18]\]. Care was taken to avoid contamination with signal from the blood pool. Following offline image co-registration and motion correction, T1 values were determined by fitting an exponential model to the measured data applying Look-Locker, noise and heart rate correction, as previously described \[[@CR13]-[@CR16]\]. In addition to the T1 measurements of native myocardium and blood pool, we calculated the myocardial partition coefficient (λ) and extracellular volume fraction (ECV) according to the formulas \[[@CR19]\]:Figure 1**Illustration of T1 measurements by ROI placements in septal myocardium (A), blood pool (B), and by coverage of myocardium in short axis slice (SAX) (C).***λ* = *ΔR*1~*myocardium*~/*ΔR*1~*blood*~ where *R*1 = 1/*T*1 measured before and twenty minutes after GBCA administration.ECV = *λ*(1 − hematocrit).

Statistical analysis {#Sec7}
--------------------

Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA, version 20.0). Normality of distributions was tested with the Kolmogorov-Smirnov statistic. Categorical data are expressed as percentages, and continuous variables as mean ± SD or median (interquartile range), as appropriate. For comparison of two and more than two normally distributed variables, Student's *t*-test and one-way analysis of variance (ANOVA, with Bonferroni's post-hoc test) as appropriate. Associations were explored by single and multivariate linear regressions. Images considered of sufficient quality and free of artefacts \[[@CR20]\] to be deemed diagnostic were used for analysis of septal native T1. Inter- and intraobserver reproducibility and agreement of post-processing approaches was assessed according to the method of Bland and Altman. Because hematocrit has been only available in 34% of all subjects, missing values for calculation of ECV were obtained using multiple imputation method \[[@CR21]\]. All values are reported as mean ± SD and a p-value of less than 0.05 was considered statistically significant.

Results {#Sec8}
=======

Contribution of cases per recruiting centers was as follows: KCL (n = 146, 68%; 1.5 T: n = 101, 3 T, n = 45), DHZB (n = 46, 22%, all 3 T), UL (n = 14, 7%, all 3 T), StVU (n = 9, 4%, all 1.5 T). Subject characteristics for healthy volunteers and low risk patients are presented in Table [1](#Tab1){ref-type="table"}. There were no differences in mean age or gender representation and routine CMR measures between field strengths (p \> 0.05), as well as between the two groups (Figure [2](#Fig2){ref-type="fig"}).Table 1**Subject characteristicsVariablesHealthy volunteersLow risk patientsSig.(n = 102)(n = 113)(p-value)**Age (years)41 ± 1744 ± 140.21Gender (male(n,%))53 (52)57 (51)0.88BMI26 ± 426 ± 40.97Heart rate (bpm)66 ± 1167 ± 130.26Systolic BP (mmHg)119 ± 11121 ± 150.27Diastolic BP (mmHg)71 ± 1175 ± 90.39eGFR (ml/m^2^)92 ± 3697 ± 250.57Hematocrit (%)40 ± 0.0441 ± 0.040.91LV-EDV index (ml/m^2^)79 ± 1577 ± 130.41LV-ESV index (ml/m^2^)30 ± 830 ± 70.79LV-EF (%)63 ± 562 ± 50.37RV-EF (%)59 ± 758 ± 70.89LV mass index (g/m^2^)51 ± 1253 ± 130.21LA area (g/m^2^)22 ± 421 ± 40.49**1.5 T(n = 34)(n = 58)**Native T1~myocardium~ (msec)950 ± 21952 ± 230.66Native T1~blood~ (msec)1551 ± 1151572 ± 1110.36Postcontrast T1 ~myocardium~ (msec)415 ± 113406 ± 940.77Postcontrast T1 ~blood~ (msec)291 ± 122278 ± 1070.51λ0.44 ± 0.060.43 ± 0.080.72ECV0.25 ± 0.040.26 ± 0.060.32**3 T(n = 32)(n = 55)**Native T1~myocardium~ (msec)1052 ± 231053 ± 240.51Native T1~blood~ (msec)1736 ± 1391716 ± 1490.64Postcontrast T1 ~myocardium~ (msec)421 ± 131402 ± 1170.81Postcontrast T1 ~blood~ (msec)277 ± 106250 ± 1120.69λ0.44 ± 0.070.43 ± 0.090.46ECV0.26 ± 0.040.26 ± 0.060.72BMI -- Body mass index, BP -- blood pressure. Student *t*-test, P \< 0.05 is considered significant. A total of 179 subjects underwent a contrast-enhanced study (healthy volunteers, n = 66; patients, n = 113). Student *t*-test or one-way ANOVA, P \< 0.05 is considered significant.Figure 2**Concordance of T1 values and routine CMR measures between healthy volunteers (n = 102) and a subgroup of patients with low pretest likelihood of cardiovascular disease (n = 113).**

Comparison of T1 values per field strength {#Sec9}
------------------------------------------

In healthy controls, mean native T1 values were 950 ± 21 msec at 1.5 T and 1052 ± 23 at 3 T, whereas λ and ECV values were 0.44 ± 0.06 and 0.25 ± 0.04 at 1.5 T, and 0.44 ± 0.07 and 0.26 ± 0.04 at 3 T, respectively (Table [1](#Tab1){ref-type="table"}). There were no significant differences between healthy controls and low risk subjects in routine CMR parameters and T1 values (Figure [2](#Fig2){ref-type="fig"}). Mean native T1 was significantly higher at 3 T compared to 1.5 T for both groups. There was a close association between the two partition coefficient variables: 1.5 T: r = 0.92, 3 T: r = 0.94, (p \< 0.001 for both).

Comparison of T1 values for post-processing approaches {#Sec10}
------------------------------------------------------

Age-gender matched samples of subjects from each site (n = 7 per site, a total of 28) were examined for segmental values and average T1 value per short-axis (SAX) slice (Figure [3](#Fig3){ref-type="fig"}). As expected, there were considerable regional differences in T1 values in controls with the highest values in inferior septal segments (segment 9, native T1 (msec) -- 1.5 T: 995 ± 23; 3 T: 1107 ± 21) and the lowest values in anterolateral segments (segment 12, native T1 (msec) -- 1.5 T 902 ± 59; 3 T: 1029 ± 67) at both field strengths (native T1, one-way ANOVA for 6 segments comparisons: 1.5 T: F = 8.0, p \< 0.01; 3 T F = 3.1, p \< 0.05). Compared to septal native T1 (msec, 1.5 T: 3 T:), native T1 values averaged per SAX slice were significantly lower (native T1 (msec) septal vs. SAX: 1.5 T: 957 ± 22 vs. 941 ± 58; 3 T 1043 ± 23 vs. 1072 ± 63, p \< 0.05) \[[@CR16]\].Figure 3**Segmental variations of T1 values in midventricular short axis slice (SAX, segments 7--12) at 1.5 T and 3 T field strengths.** Bull's eye with annotated segments in midventricular SAX slice.

Comparisons of T1 values between the core lab and investigator sites {#Sec11}
--------------------------------------------------------------------

There was close agreement between T1 values obtained in core-lab and locally for all sites for native septal and SAX T1 measurements (a mixed sample of 1.5 T and 3 T cases from all sites, n = 9, p = 0.57 and p = 0.42; between sites comparisons, repeated measures ANOVA) (Figure [4](#Fig4){ref-type="fig"}). Post-contrast values showed lower concordance for both septal and SAX T1 measurements (p = 0.104 and p = 0.08).Figure 4**Concordance between measurements obtained at core lab and at participating sites for native and postcontrast septal and short axis slice (SAX) measurements in a random sample of 9 cases from all sites (KCL -- King's College London, Leeds -- University of Leeds, DHZB -- Deutsches Herzzentrum Berlin (German Heart Institute Berlin), Sydney -- Vincent University, Sydney Australia.**

Comparisons of T1 indices for age, gender, contrast dose and investigator sites {#Sec12}
-------------------------------------------------------------------------------

Age groups were determined by separating the entire study population into quartiles (group 1: ≤30 years (1.5 T, n = 27, 3 T = 26), group 2: 31 and 42 years (1.5 T, n = 28, 3 T = 27); group 3: 42 and 53 years (1.5 T, n = 27, 3 T = 24), group 4: ≥ 53 years (1.5 T, n = 28; 3 T = 28) (Figure [5](#Fig5){ref-type="fig"}). T1-values were similar across the age groups for any field strength (Table [2](#Tab2){ref-type="table"}). Comparisons of mean values between the participating sites revealed no significant difference for native T1 (F = 1.9, p = 0.86), λ (F = 0.4, p = 0.89) and ECV (F = 0.3, p = 0.91). Mean time from administration to post-contrast T1 mapping acquisition was 18 ± 4.9 min, with no significant departures between the sites (F = 2.9, p = 0.61). A sub-analysis for GBCA dose (Gadovist® 0.1 mmol/kg vs. 0.15 mmol/kg vs. 0.2 mmol/kg) revealed a significant difference for λ and ECV (Table [3](#Tab3){ref-type="table"}) between the protocols.Figure 5**Distribution of native T1 values for age and gender.** Age groups were determined by separating the entire study population into quartiles (group 1: ≤30 years (1.5 T, n = 27, 3 T = 26), group 2: 31 and 42 years (1.5 T, n = 28, 3 T = 27); group 3: 42 and 53 years (1.5 T, n = 27, 3 T = 24), group 4: ≥ 53 years (1.5 T, n = 28; 3 T = 28).Table 2**T1 values per age, gender and contrast dose1.5 T3 T1.5 T3 TSig.(n = 110)(n = 105)(n = 92)(n = 87)(p-value)Age categoriesNative T1 (msec)ECV**Group 1952 ± 221053 ± 260.24 ± 0.030.24 ± 0.02Group 2953 ± 251057 ± 240.25 ± 0.040.25 ± 0.03Group 3957 ± 251058 ± 250.24 ± 0.030.24 ± 0.04Group 4965 ± 181052 ± 240.23 ± 0.040.23 ± 0.03Sig. (p-value)F = 1.30, p = 0.28F = 1.16, p = 0.21F = 1.09, p = 0.46F = 1.11, p = 0.36**GenderNative T1 (msec)ECV**Males955 ± 231053 ± 250.23 ± 0.040.24 ± 0.05Females957 ± 231054 ± 250.25 ± 0.030.25 ± 0.05Sig. (p-value)0.440.870.360.78Age groups were determined per quartiles: group 1: ≤30 years (1.5 T, n = 27, 3 T = 26), group 2: 31 and 42 years (1.5 T, n = 28, 3 T = 27); group 3: 42 and 53 years (1.5 T, n = 27, 3 T = 24), group 4: ≥ 53 years (1.5 T, n = 28; 3 T = 28). Student *t*-test or one-way ANOVA, P \< 0.05 is considered significant.Table 3**Comparisons of hybrid measures for different doses of gadolinium contrast agent as per local protocol (Gadovist® 0.1 mmol/kg vs. 0.15 mmol/kg vs. 0.2 mmol/kg)1.5 T3 T1.5 T3 TSig.(n = 92)(n = 87)(n = 92)(n = 87)(p-value)Gadovist® dose**λ**ECV**0.1 mmol/kg (n = 9/0)0.53 ± 0.13/0.31 ± 0.08/0.15 mmol/kg (n = 17/14)0.46 ± 0.060.49 ± 0.070.27 ± 0.040.30 ± 0.040.750.2 mmol/kg (n = 73/66)0.40 ± 0.050.43 ± 0.070.24 ± 0.040.26 ± 0.05**0.05**Sig. (p-value)**F = 9.6, p \< 0.01p \< 0.05F = 5.6, p = 0.06P \< 0.01**

Analysis of relationships {#Sec13}
-------------------------

There was a trend of a positive association between native T1 and age at 1.5 T (r = 0.21, p \< 0.1 for all), which was stronger in the male cohort (r = 0.23, p = 0.04) (Figure [6](#Fig6){ref-type="fig"}). There were no such associations noted on 3 T. Comparisons of native T1, λ and ECV by gender revealed no significant differences at any field strength (p \> 0.05 for all). Native T1 was mildly associated with LV-EDV, LV-ESV and LV mass at both field strengths (native T1: 1.5 T: r = 0.21, p = 0.04; r = −0.24, p = 0.02; r = −0.23, p = 0.03; 3 T: r = 0.13, p = 0.14; r = −0.21, p = 0.05, r = −0.19, p = 0.07). Results of inter and intraobserver reproducibility and agreement are provided in Additional file [1](#MOESM1){ref-type="media"} (Figure [7](#Fig7){ref-type="fig"}).Figure 6**Relationship between native T1 and age separately for field strengths.**Figure 7**Interobserver and intraobserver reproducibility of native T1 values.**

Discussion {#Sec14}
==========

We demonstrate that myocardial T1 values obtained in an investigator-led, single vendor, multicenter study based on similar imaging infrastructure and unified imaging parameters, can be reliably reproduced at the core lab as well as the participating sites by standardized image acquisition and post-processing approach. We provide reference values for native T1 and hybrid measures for 1.5 and 3 T magnetic field strengths in healthy human myocardium. The present study provides a proof of transferability of a T1 mapping methodology beyond a single (and expert) center and suggests a pathway towards a wider use of T1 mapping.

A substantial body of evidence suggests that T1 mapping is sufficiently accurate, reproducible and robust to enter into clinical translational pathway; T1-values were found abnormal in a variety of cardiomyopathies and permit discrimination between normal and abnormal myocardium. Thus far, a couple of studies reported on the associations with outcomes, albeit short-term, in a selected patient population and single centre set-ups \[[@CR22],[@CR23]\]. Difficulties for immediate clinical translation also relate to the ongoing technical evolution of T1 mapping sequences, scarcity of multicenter and prospective controlled studies as well as outcome evidence in subgroups and in large populations \[[@CR11],[@CR24]\]. This is the first study to provide reference values for myocardium healthy humans, including native T1 and ECV based on a unified T1 mapping methodology at both field strengths, in a multicenter setting. The average T1 values obtained at 1.5 T field strength are closest to the segmental values obtained by Messroghli et al. \[[@CR13],[@CR20],[@CR25]\] using MOLLI in its original form, 3(3)3(3)5, which was also used for the current data acquisition. Advances in MRI scanning equipment with improved coils and shimming, combined with a rigorous postprocessing approach with motion correction, as well as considerably greater sample size, may explain the lower spread of native T1 values observed in the present study. Subsequent generations of MOLLI sequence, which introduced several parameter modifications, most noticeably a lower flip angle of 35° (compared to 50° in the original sequence), showed similar average myocardial native T1 values in healthy volunteers (Messroghli: 939 ± 24 msec; Piechnik, 976 ± 46 msec) \[[@CR26],[@CR27]\], and were also implemented across other vendor platforms. A series of publications from a single centre (National Institutes of Health, NIH) revealed either similar values at 1.5 T (Gai et al. 986 ± 168 msec, FA = 50° \[[@CR28]\]; Liu et al.: native T1: 977 ± 42 msec, FA 35° \[[@CR12]\]) or higher native T1 values (Nacif et al. native T1: 1034 ± 56 msec, FA 35°) \[[@CR29]\], with considerably greater scatter. T1 relaxation times increase with higher field strength, which is also reflected in our findings: myocardial native T1 values at 3 T are approximately 100 msec longer in comparison to 1.5 T. This observation is concordant with previous studies, including by Piechnick et al. (average SAX 1169 ± 45 msec) \[[@CR27]\], and several publications from the NIH (Kawel et al. 1286 ± 59 msec \[[@CR30]\]; Lee et al. (1315 ± 39 msec) \[[@CR31]\], and more recently, Von Knobelsdorff-Brenkenhoff et al. (1159 ± \~73 msec) \[[@CR32]\]. The magnitude of native T1 values at 3 T observed in the present multicenter study concord with the values in patient cohort comparisons studies we have reported on previously \[[@CR14]-[@CR16]\], supporting the unchanging source of results based on a uniform imaging platform. We also provide further insights into the reference ranges for λ and ECV based on a MOLLI sequence at both field strengths based on the bolus technique \[[@CR19],[@CR22],[@CR30]\]. Our findings concord with previous reports concerning the average and spread of ECV values in healthy subjects (at 1.5 T: Liu et al. 0.27 ± 0.03 (calculated as an average of values for men: 0.26 ± 0.03 and women: 0.28 ± 0.03) \[[@CR12]\], Wong et al. \~0.24 ± 0.02 \[[@CR22]\]; at 3 T: Kawel et al. \~0.29 ± 0.03 (estimated from the Figure [2](#Fig2){ref-type="fig"} at \~20 min time-point) \[[@CR30]\], Lee et al. 0.27 ± 0.10 \[[@CR31]\]), and the independency of the calculated parameters from the field strengths.

Sequence parameters, vendors' specific set-up and standardized acquisition in part explain the observed diversity in T1 values in the above studies. A standardized approach to postprocessing is an additional important consideration for reproducibility and spread of T1 measurements, allowing robust discrimination between health and disease. We and others have previously shown that there are significant regional variations of native T1-values in SAX slices of normal subjects \[[@CR16],[@CR27],[@CR33]-[@CR35]\], with differences between the septal and lateral segments ranging between 60 to 150 msec. We have previously shown that native T1 measurement in the septum provide the most robust post-processing approach with an excellent intra-observer and inter-observer reproducibility irrespective of the field strength \[[@CR14]-[@CR16]\]. We now show that this post-processing approach is robust also in a multicenter setting, providing meaningful values on the expected reference ranges in healthy myocardium. Regional variation in segmental values may also account for a higher spread of values in some of the above studies, because T1 measurements in average SAX approach integrate native T1 values observed in all myocardial segments. It is unlikely that these regional differences represent a true difference in tissue composition.

We found no relationship between T1 values and age. Several previous publications showed decreasing native T1 values \[[@CR36]\] or increasing ECV values with age \[[@CR12],[@CR22]\]. Whereas decreasing trend with age is difficult to explain, the latter studies used a cross-sectional study design and investigated subclinical or overt disease, respectively. We have shown previously that T1 values increase with age in patients with cardiomyopathies \[[@CR15]\]. The discrepancy with previous results in healthy cohorts indicates that characterisation of healthy aging of the myocardium is challenging and complicating simple comparisons of age-related changes in T1 values. Previous studies also showed associations with gender, whereby age-dependency was stronger in men, and older females displaying higher native T1 or hybrid values \[[@CR12],[@CR36]\]. We found no gender differences in T1 values and a weak association for hybrid indices with males at 1.5 T; however, we could not reproduce such trend at 3 T. Of note, in a selected subgroup of subjects with very low cardiovascular risk, Liu et al. showed no ECV differences between women and men \[[@CR12]\], analogous to our findings. It is possible that age and gender differences in T1 values may relate to subclinical and clinical disease in cross-sectional studies, but may not be a profound feature in healthy aging. Lastly, whereas all sites used a single type of GBCA, gadobutrol, we reveal that non-uniformity of contrast agent doses leads to appreciable differences in hybrid indices at both field strengths. These findings were not expected, as it is generally considered that λ and ECV account for most of these sources of variation, which otherwise complicate cross-sites comparisons \[[@CR9],[@CR28]\].

Limitations {#Sec15}
-----------

A few limitations apply to this study. It is recognized that the MOLLI variant used in our study affords a greater precision in terms of tissue characterisation (i.e. discrimination between health and disease) compared to the measurements derived from other MOLLI scheme variants (which are more accurate in terms of T1 value estimation) \[[@CR10],[@CR11]\], therefore, our ECV calculation is likely to be more precise. Ongoing advances and optimization of MOLLI schemes and pulse sequence parameters have shown that estimation of true T1 values can be obtained with greater accuracy \[[@CR10],[@CR11]\]. However whilst improved accuracy is attainable, high precision of T1 estimates supporting ability to discriminate between health and disease is fundamental, supporting diagnostic and prognostic role of a biomarker in clinical use. Both, precision and high discriminatory ability have been demonstrated for the approach chosen in the current study \[[@CR14]-[@CR16]\]. It may be argued that optimized FA (e.g. 35°) may be superior to our choice of 50° due to a higher SNR and less susceptibility to off-resonance effects \[[@CR25],[@CR37]\]. However, a higher FA also leads to stronger magnetisation transfer effects, which differ between normal and abnormal myocardium, adding to the discriminatory ability of the chosen method \[[@CR38]\]. Asymptomatic healthy subjects represent an ideal target population for derivation of normal ranges. In selecting healthy volunteers in our study, we strived to also account for exclusion of subclinical disease by a further inclusion criterion of normal findings on routine CMR \[[@CR17],[@CR39]\]. These same rigorous inclusion criteria were applied to the subgroup of normotensive low risk patients, primarily intended to compensate for the lower number of contrast studies in healthy volunteers. Because groups were similar for clinical characteristics and routine CMR findings (and subsequently T1 values), we believe that bias introduced by their inclusion in age-gender related comparisons is negligible. Hematocrit, which is used in ECV calculation has only been available in a minority of subjects and has not been sampled at the time of CMR studies \[[@CR9]\]. Thus, normal ranges for hybrid measures may bear inaccuracies. In the present study we controlled for, reported on or assessed many of the influences, which complicate T1 values comparisons, including CMR platform, technique, pulse sequence parameter selections, field strength, type of GBCA and post-processing of T1 measurement. While a single vendor platform might potentially be perceived as a limitation to a wider transferability of our results, the multicenter nature of our data overcomes several limitations by delivering evidence, which is fundamental and immediately useful to the centers using same hardware set-up. This adds to the future potential of providing T1 mapping as a commercial clinical application as the evidence continues to emerge. Evidence for robustness of clinical applications also enhances the chances for multivendor agreements, providing the clarity on a common minimum standard for clinical application of a T1 mapping sequence.

Conclusions {#Sec16}
===========

In this study we provide a proof of transferability for a T1 mapping methodology beyond a single (expert) center, suggesting a pathway for an extended utility of T1 mapping. Based on a unifying and standardized imaging and postprocessing approach we provide reference T1 values in healthy subjects at both field strengths.

Additional file {#Sec17}
===============

Additional file 1:**Summary of the inter and intra-observer reproducibility sub-study of T1 measurements.**
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